Curanex Completes GMP Batch, Reports Favorable Toxicology, Targets Q4 2026 IND
Curanex completed a GMP-compliant pilot-scale batch of Phyto-N and a 28-day dose-range toxicology study in rats and dogs with no treatment-related adverse findings, supporting its planned Q4 2026 IND submission for ulcerative colitis. The company also expanded its pipeline to target a $2.54 billion cancer cachexia market and holds $4 million cash.
1. IND-Enabling Milestones
During Q1 2026, Curanex produced a GMP-compliant pilot-scale batch of Phyto-N and completed a 28-day dose-range toxicology study in rats and dogs. No treatment-related adverse findings were observed at any dose, supporting dose selection and strengthening the IND-enabling package for ulcerative colitis.
2. Pipeline Expansion to Cancer Cachexia
Post-Q1, the company added cancer cachexia as a core indication, targeting a market estimated at $2.54 billion in 2024 and projected to reach $3.90 billion by 2033. The move leverages Phyto-N’s anti-inflammatory and metabolic modulation potential in a condition with no FDA-approved therapies.
3. Financial Position and Outlook
As of March 31, 2026, Curanex held $4.0 million in cash and equivalents, funding toxicology, pharmacokinetic, manufacturing, and regulatory activities through the next key milestones. The company remains focused on completing GLP studies and preparing for its planned Q4 2026 IND submission.